Several monoclonal antibodies (mAbs) preventing integrin interaction with FN, including those against αvβ6 and α5β1, have shown excellent pre-clinical promise in breast and glioma models, respectively [126,127], highlighting the value of this axis. Here, FN1 is linked to central nervous system cancer.